Skip to main content

Table 1 Clinical and pathological characteristics of the patients.

From: A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole

Parameter

n (%)

Histological diagnosis*

 

   IDC

67 (70.5)

   ILC

16 (16.8)

   Others

12 (12.6)

Histological grade

 

   I

29 (55.8)

   II

19 (36.5)

   III

4 (7.7)

Tumor size (T)

 

   T2

76 (80.0)

   T3-T4

19 (20.0)

Lymph node involvement (N)

 

   N0

76 (80.0)

   N1-2

19 (20.0)

Stage

 

   IIa

65 (68.4)

   IIb

20 (21.1)

   IIIa-IIIb

10 (10.5)

ER

 

   Negative

5 (5.3)

   10-40%

8 (8.4)

   40-70%

25 (26.3)

   > 70%

57 (60.0)

PgR

 

   Negative

28 (29.5)

   10-40%

18 (18.9)

   40-70%

24 (25.3)

   > 70%

25 (26.3)

HR**

 

   ≤ 40%

10 (10.5)

   > 40%

85 (89.5)

HER2

 

   Negative

39 (41.1)

   +

24 (25.3)

   ++

22 (23.2)

   +++

10 (10.5)

Ki67

 

   Negative

40 (55.6)

   Positive

32 (44.4)

Response to letrozole

 

   Non responders

60 (63.2)

   Responders

35 (36.8)

Progression status

 

   No progression

77 (81.1)

   Progression

18 (18.9)

Surgery status

 

   No surgery

30 (32.0)

   Surgery

65 (68.0)

  1. *IDC, Infiltrating ductal carcinoma; ILC, Infiltrating lobular carcinoma; Others (Mucinous, tubular and medullar carcinomas).
  2. **Hormonal status was considered as ≤ 40% when either estrogen and progesterone receptors were ≤ 40%, and as > 40% when at least one of the receptors were > 40%.